European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fi... (00 employees.Since it was founded in 188...)

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

Date:10/24/2008

00 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.com.

Duloxetine for major depressive episodes, diabetic peripheral neuropathic pain and generalised anxiety disorder is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Germany, Greece, Italy and Spain. In Germany, Lilly and Boehringer Ingelheim market duloxetine for major depressive episodes under the brand name Cymbalta, and market the product for diabetic peripheral neuropathic pain as Ariclaim(R). In Greece, Italy and Spain Lilly markets the product as Cymbalta and Boehringer Ingelheim markets the product as Xeristar(R). In the United States, Cymbalta is marketed by Lilly and Quintiles. In Japan, duloxetine is co-developed and co-marketed by Lilly and Shionogi & Co., Ltd.

Duloxetine for stress urinary incontinence is marketed by Lilly under the brand name Yentreve(R).

(1) Russell, IJ, et al. Efficacy and Safety of Duloxetine for Treatment of Fibromyalgia in Patients With or Without Major Depressive Disorder: Results From A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Trial, Pain. 2008.

(2) Arnold, L, et al. A Randomized, Double-Blind, Placebo Controlled Trial of Duloxetine in the Treatment of Women with Fibromyalgia With or Without Major Depressive Disorder. Pain. 2005; 119 (1-3): 5-15

(3) Arnold, L, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine with Placebo in the Treatment of Fi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma

Post Your Comments:

(Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...

(Date:5/23/2013)... , May 23, 2013 BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time. About BioScrip BioScrip, ...

(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...

(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...

Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2 PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2 PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3 VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2 VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3

[0] Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology [0] BioScrip To Present At Jefferies 2013 Global Healthcare Conference [0] PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 [0] VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials

... Gen-Probe Incorporated (NASDAQ: GPRO ) today ... revenues in the quarter grew 16%, to a new record ... 18%, to a new high of $0.72. "Gen-Probe ... fourth quarter while clinical diagnostics revenues continued their solid growth," ...

... Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer ... prescription medications, announced today that the company plans to ... beginning of the forthcoming month of March 2012 ... 1 Technologies is authorized to repurchase up to 10 ...

... New York, February 14, 2012 ... Oxygen Concentrator Market Shares, Strategies, and Forecasts, Worldwide, 2012 ... that it has a new study on Oxygen Concentrator ... has 524 pages, 191 tables and figures. , ,Reimbursement ...

Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018

(Date:5/23/2013)... the world,s most popular fruit, can be made both ... GM varieties. , "Working with GM tomatoes that ... of a specific compound, allows us to pinpoint exactly ... Martin from the John Innes Centre. , The research ... health and shelf life characteristics because even higher levels ...

(Date:5/23/2013)... than 13,000 ships per year, carrying more than 284 million ... roughly $1.8 billion dollars in toll fees for the Panama ... 55 million gallons of water are used from Gatun Lake, ... million people living in the isthmus. , However, the ... 20 percent of the ships at sea, has demanded change. ...

(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...

Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2 Reforestation study shows trade-offs between water, carbon and timber 2 Reforestation study shows trade-offs between water, carbon and timber 3 UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2

[0] The world's favorite fruit only better-tasting and longer-lasting [0] Reforestation study shows trade-offs between water, carbon and timber [0] UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis

... forest products industry has been growing rapidly since ... U.S. economy annually. Examples of nontimber forest products ... medicinal and herbal products, and specialty floral and ... U.S.-grown herbs used to satisfy increasing consumer demand ...

... with her studies challenging a popular theory that an ... evidence asserting her position. Gerta Keller, whose studies ... States, Mexico and India have led her to conclude ... likely culprits in the demise of the Earth,s giant ...

... & Life Sciences Division (DBIO) of the Special Libraries ... of biology and medicine over the last 100 years ... among them. In the poll, 686 DBIO members ... "Journals of Land Invertebrates" category. Annals celebrated its 100th ...

Cached Biology News:Decreasing deer damage 2 Decreasing deer damage 3 Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 2 Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 3 Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 4 'Annals of the ESA' selected as one of 100 most influential journals 2

Decreasing deer damage Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 'Annals of the ESA' selected as one of 100 most influential journals

... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...

HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....

... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...

Request Info...

Biology Products:

Pig Interferon Alpha Bioassay Services from PBL InterferonSource Hybridization module,Hypro100 from Thermo Scientific Rat Interferon Alpha Bioassay Services from PBL InterferonSource Alkaline Phosphatase, shrimp from Roche Applied Science